Email an article from "The Bahamas Weekly" to a friend.

Okyanos announces new treatment option for Diffuse Scleroderma based on STAR Trial Protocol


Okyanos-team.jpg
Freeport, Grand Bahama (October 4, 2017) Okyanos Center for Regenerative Medicine today announced that Okyanos is now offering a new and advanced protocol for diffuse scleroderma based on the well-established protocol implemented in the STAR clinical trial.
 
Earlier this year Cytori Therapeutics, Inc., reported the findings of the STAR trial which used adipose derived regenerative cells (ADRCs) to treat scleroderma affecting the hands and fingers. Using 19 leading medical centers in the United States, the double-blind, randomized, placebo-controlled trial enrolled and evaluated 88 participants, 51 of whom had diffuse scleroderma, a more severe form of the disease...

When you confirm, the article summary above, will be emailed to your chosen email address.

Your Email Address:
Your Name:

Please enter the email address to send to:

Friend's Email Address:
Friend's Name:

 

logo